Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol.
Level 5 - mechanism / opinion, no new human data
Narrative commentary summarizing multi-society clinical practice guidelines without primary data or systematic review methodology.
PubMed 31286451 · doi:10.1007/s40256-019-00358-0
What was done
This paper provides an expert overview summarizing the core updates and clinical recommendations of the 2018 multi-society (AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA) guideline on the management of blood cholesterol.
What was found
The abstract reports key structural updates in the 2018 guidelines rather than quantitative trial data: primary prevention is stratified into low (<5%), borderline (5% to <7.5%), intermediate (7.5% to <20%), and high (≥20%) ASCVD risk; clinical "risk enhancers" and coronary artery calcium scoring are integrated to refine treatment or de-risk patients; "very high risk" ASCVD is defined; and an LDL-C threshold of ≥70 mg/dL on maximally tolerated statins is established to initiate ezetimibe, with PCSK9 inhibitor consideration for very high-risk individuals.
Why it matters
The summary clarifies how clinicians can use refined risk assessment tools and specific non-statin thresholds to target lipid-lowering therapies to patients at highest cardiovascular risk.
Limits
This publication is a descriptive narrative summary of practice guidelines, containing no original clinical trial data, primary human measurements, or quantitative efficacy endpoints.
Cited by
- supports Cardiovascular and lipid guidelines establish an LDL cholesterol level of 190 mg/dL or greater as a threshold mandating clinical intervention and statin therapy, often driven by underlying genetic conditions such as LDL receptor abnormalities.